The increasing availability of biosimilar medicines in MENA regions provides an opportunity for patients to have access to traditionally more expensive biologic medicines. However, lack of understanding the development pathway for biosimilars combined with the availability of non-comparable biologics, also known as intended copies, may undermine physician confidence in prescribing legitimate biosimilar medicines. The regulators also need to ensure that…